Ferrada @maferradastrong et al. HSCT in VEXAS. 20 evaluated. Indications refractory disease or haematologic abnormalities. Completed in 2, ongoing in 2. @RheumNow #ACR22 Abstr#1568 https://t.co/01SeHQcIsh https://t.co/XCgz4cTQCJ